Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Thromboembolic Disease and Its Complications
share announcement

Thromboembolic Disease and Its Complications

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 2149

Special Issue Editor

Prof. Dr. Roberto Pola

E-Mail Website
Guest Editor
Section of Internal Medicine and Thromboembolic Diseases, Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Interests: thrombosis; pulmonary embolism; anticoagulation; antithrombotic therapies; cardiovascular diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The therapeutic management of venous thromboembolic diseases has undergone substantial advancements in recent years, especially due to the introduction of direct oral anticoagulants and the development of novel therapeutic strategies. Nonetheless, several gray areas remain, and they need to be further explored. An example is the prevention and treatment of venous thromboembolism in subjects with cancer, especially those with cancers of the gastrointestinal system and the genito-urinary tract. Another example is the treatment of thrombosis in unusual sites, such as the splanchnic veins, the cerebral veins, or the veins of the retina. Even more interesting is the issue of treating subjects with high hemorrhagic risk, as are the cases of individuals who have low platelet count, reduced kidney function, older age, previous bleeding history, or hereditary hemorrhagic diseases. Of interest are also the novel inhibitors of coagulation factor XI, which are currently under investigations for the prevention and treatment of thromboembolic diseases. Early diagnosis and proper treatment are crucial in reducing the acute and chronic complications of thromboembolic diseases. Preventing and treating post-thrombotic syndrome, and thromboembolic pulmonary hypertension is also a topic that deserves attention and investigation. In this Special Issue, we encourage authors to submit papers on the prevention, diagnosis, and treatment of venous thromboembolic diseases and their complications.

Prof. Dr. Roberto Pola
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • venous thrombosis
  • pulmonary embolism
  • post-thrombotic syndrome
  • thromboembolic pulmonary hypertension
  • anticoagulation
  • antithrombotic therapies

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 529 KiB  
Article
Clinical Correlates of In-Hospital Mortality in Patients Undergoing Inferior Vena Cava Filter Placement for Acute Deep Vein Thrombosis
by Enrica Porceddu, Rosa Talerico, Gabriele Ciasca, Giulia Cammà, Riccardo Di Santo, Matilde Peri, Alessandro Cina, Roberto Pola and Angelo Porfidia
J. Clin. Med. 2024, 13(8), 2285; https://doi.org/10.3390/jcm13082285 - 15 Apr 2024
Viewed by 366
Abstract
Background: It is reasonable to place an Inferior Vena Cava Filter (IVCF) when an acute deep vein thrombosis (DVT) of the lower limbs occurs in a patient with absolute contraindication to therapeutic anticoagulation. An additional potential reason for placing an IVCF is the [...] Read more.
Background: It is reasonable to place an Inferior Vena Cava Filter (IVCF) when an acute deep vein thrombosis (DVT) of the lower limbs occurs in a patient with absolute contraindication to therapeutic anticoagulation. An additional potential reason for placing an IVCF is the need to stop therapeutic anticoagulation in a patient with acute DVT who must undergo urgent non-deferrable surgery. However, IVCFs are often used outside of such established indications and many authors argue about their actual utility, especially in terms of survival. In this retrospective study, we looked for clinical correlates of in-hospital mortality among patients who underwent IVCF placement, limiting our analysis to the cases for which a correct indication to IVCF placement existed. Methods: We retrospectively analyzed the electronic database of our University Hospital, searching for consecutive hospitalized patients who had acute DVT and underwent IVCF placement because of an established contraindication to therapeutic anticoagulation and/or because it was necessary to stop anticoagulation due to urgent surgery. The search covered the period between 1 January 2010 and 31 December 2020. Results: The search resulted in the identification of 168 individuals. An established contraindication to therapeutic anticoagulation was present in 116 patients (69.0%), while urgent non-deferrable surgery was the reason for IVCF placement in 52 patients (31.0%). A total of 24 patients (14.3%) died during the same hospital stay in which the IVCF was placed. Mortality rate was significantly higher in patients with a contraindication to anticoagulation than in patients who underwent IVCF placement because of urgent surgery (19.0% vs. 3.8%, OD 5.85 vs. 0.17). In-hospital mortality was also significantly higher among patients with chronic kidney disease and those who needed blood cell transfusion during hospitalization. Conclusions: This study provides novel information on clinical correlates of in-hospital mortality among patients with acute DVT who undergo IVCF. Prospective observational studies are needed to substantiate these findings. Full article
(This article belongs to the Special Issue Thromboembolic Disease and Its Complications)
►▼ Show Figures

Figure 1

11 pages, 493 KiB  
Article
The Application of Existing Risk Assessment Models (RAMS) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin Lymphoma
by Mohammad Ma’koseh, Alaa Abufara, Dana Albaghdadi, Ruba Ghalayni, Sarah Abdel-Razeq, Eman Alzughali, Fadwa Abdel Rahman, Yazan Alhalaseh, Khalid Halahleh and Hikmat Abdel-Razeq
J. Clin. Med. 2024, 13(2), 436; https://doi.org/10.3390/jcm13020436 - 12 Jan 2024
Viewed by 696
Abstract
Background: A majority of patients included in risk assessment models (RAMs) developed to predict venous thromboembolic events (VTE) in lymphoma were non-Hodgkin lymphoma. Our study aims to evaluate the incidence and predictors of VTE, utilizing different RAMs, in patients with classic Hodgkin lymphoma [...] Read more.
Background: A majority of patients included in risk assessment models (RAMs) developed to predict venous thromboembolic events (VTE) in lymphoma were non-Hodgkin lymphoma. Our study aims to evaluate the incidence and predictors of VTE, utilizing different RAMs, in patients with classic Hodgkin lymphoma (cHL) treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD). Methods: Adult patients with cHL, treated and followed at our center, were included. Correlations between different variables, Khorana score, and thrombosis in lymphoma (ThroLy) RAMs with VTE were examined using Fisher’s exact test and logistic regression analysis. Results: A total of 321 patients were included, with a median age of 29 (range: 18–83) years. Of them, 169 (52.6%) had advanced-stage disease. Combined modality treatment was given to 169 (52.6%) patients. A total of 52 (16.2%) patients had relapsed or refractory disease. VTE were reported in 15 (4.7%) patients and were mostly during the administration of first-line (n = 8, 53.3%), or salvage chemotherapy (n = 6, 40.0%). There was no correlation between a Khorana score > 2 (p = 0.689) or ThroLy score > 3 (p = 0.335) and VTE. Older age (p = 0.014) and relapsed or refractory disease (p = 0.003) significantly correlated with VTE. Conclusions: VTE are uncommon in cHL. The commonly used RAMs failed to predict VTE. However, older age and relapsed or refractory disease significantly increased this risk. Full article
(This article belongs to the Special Issue Thromboembolic Disease and Its Complications)
►▼ Show Figures

Figure 1

9 pages, 460 KiB  
Article
Survival Outcomes after Placement of Inferior Vena Cava Filters in Cancer Patients: Insights from a Comprehensive Cancer Center’s Experience
by Hikmat Abdel-Razeq, Faris Tamimi, Mohammed J. Al-Jaghbeer, Baha’ Sharaf, Rashid Abdel-Razeq, Jafar Bani Issa, Hala Abu-Jaish and Osama Salama
J. Clin. Med. 2023, 12(23), 7209; https://doi.org/10.3390/jcm12237209 - 21 Nov 2023
Cited by 1 | Viewed by 760
Abstract
Background: Inferior vena cava (IVC) filters serve as a vital intervention when systemic anticoagulation proves ineffective or contraindicated, particularly in the context of cancer patients. This study aimed to provide real-world insights into the outcomes of cancer patients following IVC filter placement. Patients [...] Read more.
Background: Inferior vena cava (IVC) filters serve as a vital intervention when systemic anticoagulation proves ineffective or contraindicated, particularly in the context of cancer patients. This study aimed to provide real-world insights into the outcomes of cancer patients following IVC filter placement. Patients and methods: Cancer patients with IVC filters were retrospectively reviewed. The indications and survival outcomes following IVC filter insertion have been reported. Results: A total of 176 cancer patients with IVC filters were included in the study. The median patient age was 56 years (range: 18–88 years). Solid tumors were the most common primary cancers (n = 125, 71.0%), and the majority (n = 99, 79.2%) had the advanced-stage disease at the time of IVC insertion. The filters were inserted because of contraindications to anticoagulation (n = 99, 56.3%) or the failure of anticoagulation (n = 56, 31.8%). The median survival (range) following filter placement was only 2 (1.45–2.55) months for patients with advanced-stage solid tumors, 5 (0.62–9.38) months for patients with brain tumors, and 44 (8.59–79.41) months for those with early-stage solid tumors, p < 0.001. Conclusions: Our findings suggest that IVC filter placement offers limited benefits to patients with advanced-stage disease. The underlying tumor, stage, and life expectancy are crucial factors in the decision-making process before IVC filter insertion. Full article
(This article belongs to the Special Issue Thromboembolic Disease and Its Complications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop